A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 398 participants.

Also called NCT01105975

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 398 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01105975
Other papers using this trial's data
  • Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib Journal of the American College of Cardiology, 2015-11-17 DOI, PubMed 26564598
  • Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA, 2011-11-16 DOI, PubMed 22089718
  • Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients Journal of clinical lipidology, 2016 DOI, PubMed 27206939

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Denmark, Germany, Netherlands, Poland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01105975. Randomized; quadruple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2018-03-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
Condition
Dyslipidemia
Intervention (Drug)
LY2484595
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Simvastatin
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Placebo for LY2484595
Intervention (Drug)
Placebo for Statins
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01105975
Content hash
67ef3ffca17aabb17a4e87beaeb9f2fa45521ca5c00f4c11aa04f3b8f5398c03